BioCentury
ARTICLE | Clinical News

Medivir rises on Phase IIa OA data

September 26, 2017 8:52 PM UTC

Medivir AB (SSE:MVIR B) gained SEK14.75 (25%) to SEK74.75 on Tuesday after reporting that MIV-711 slowed the degenerative effects of moderate osteoarthritis on both bone and cartilage of the knee in the Phase IIa MIV-711-201 trial. The company said MIV-711 has the potential to be the first disease-modifying drug for OA, and now plans to seek a partner to further develop the reversible small molecule inhibitor of cathepsin K (CTSK).

In the 244-patient trial, once-daily 100 and 200 mg doses of oral MIV-711 both significantly reduced femoral joint bone area progression as measured by MRI from baseline to six months, a secondary endpoint, by about 65% vs. placebo (p<0.005 for both). Low-dose MIV-711 also led to a 70% reduction in median loss of femoral cartilage thickness vs. placebo, while high-dose MIV-711 showed a "small increase" in median cartilage thickness...

BCIQ Company Profiles

Medivir AB

BCIQ Target Profiles

Cathepsin K (CTSK)